Journal profile · Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
Bioengineering & Translational Medicine
ISSN 2380-6761 · Wiley-Blackwell · UNITED STATES
Bioengineering & Translational Medicine: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 6.16; fully open access; APC about USD 3,180; median 146 days to acceptance (93 articles, last 24 months); acceptance rate 22% (journal website); 134 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Bioengineering & Translational Medicine is published by Wiley-Blackwell and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are 3D Printing in Biomedical Research, RNA Interference and Gene Delivery and Nanoplatforms for cancer theranostics, together about 26.3% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
<em>Bioengineering & Translational Medicine</em> is a bioengineering journal of the American Institute of Chemical Engineers (AIChE).
From the journal's Aims & Scope
Research area (LetPub): Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
Main research topics OpenAlex counts of recent articles; shares are approximate
- 3D Printing in Biomedical ResearchEngineering10.9%
- RNA Interference and Gene DeliveryBiochemistry, Genetics and Molecular Biology8.1%
- Nanoplatforms for cancer theranosticsEngineering7.3%
- Tissue Engineering and Regenerative MedicineMedicine7.1%
- Nanoparticle-Based Drug DeliveryMaterials Science6.4%
- Electrospun Nanofibers in Biomedical ApplicationsMaterials Science5.9%
- Mesenchymal stem cell researchMedicine4.3%
- Wound Healing and TreatmentsMedicine4.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Engineering, Biomedical | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Engineering, Biomedical | Zone 3 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Engineering, Biomedical | Zone 2 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 6.16LetPub ·
- Impact factor (publisher)
- 6.2Publisher website ·
- Impact factor (publisher) 2025
- 6.2Publisher website ·
- CiteScore 2026-06
- 13.9LetPub ·
- CiteScore (publisher)
- 13.9Publisher website ·
- CiteScore (publisher) 2025
- 13.9Publisher website ·
- SJR 2026-06
- 1.45LetPub ·
- SNIP 2026-06
- 1.16LetPub ·
- h-index
- 73OpenAlex ·
- i10-index
- 511OpenAlex ·
- 2-year mean citedness
- 5.26OpenAlex ·
- Self-citation rate
- 1.6%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 119LetPub ·
- Articles per year (publisher) 2025
- 119Publisher website ·
- Downloads per year (publisher) 2025
- 549,414Publisher website ·
Articles by year OpenAlex count · 973 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 79 | 79 | 37 |
| 2025 | 134 | 134 | 467 |
| 2024 | 108 | 108 | 1,186 |
| 2023 | 166 | 166 | 2,909 |
| 2022 | 185 | 185 | 5,541 |
| 2021 | 84 | 84 | 3,678 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
146 daysMedian, submission to acceptance · P25–P75 109 days – 216 days
- Acceptance to online
- median 18 days (93 articles)
- Submission to online
- median 176 days
- Sample
- 93 articles with submission and acceptance dates (221 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 12 weeksLetPub ·
- Acceptance rate (publisher)
- 22%Publisher website ·
- Acceptance rate (publisher) 2025
- 22%Publisher website ·
- Submission to first decision
- 8 daysPublisher website ·
- Submission to first decision 2025
- 8 daysPublisher website ·
- Submission to acceptance 2025
- 154 daysPublisher website ·
- Acceptance to publication 2025
- 17 daysPublisher website ·
- Submission to publication (journal-reported)
- about 12 weeksDOAJ ·
- Peer review
- Single anonymous peer review, Unspecified peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,180 / GBP 1,980 / EUR 2,490 | Yes | CC BY | |
| OpenAlex | USD 2,890 / EUR 2,260 / GBP 1,800 | — | — | |
| LetPub | USD 2,750 / GBP 1,710 / EUR 2,150 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Wiley-Blackwell
- Country or region
- UNITED STATES
- Language
- English
- ISSN
- 2380-6761
- Official links
- Journal homepage ↗OpenAlex
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Bioengineering & Translational Medicine
What CAS zone is Bioengineering & Translational Medicine in?
In the 2025 upgraded edition of the CAS Journal Ranking, Bioengineering & Translational Medicine is in Zone 2 of Medicine, and in Zone 3 of the minor category Engineering, Biomedical. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Bioengineering & Translational Medicine?
The latest impact factor listed by LetPub is 6.16; CiteScore 13.9, h-index 73.
How long does peer review take at Bioengineering & Translational Medicine?
Based on the dates recorded on 93 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 146 days (interquartile range 109–216 days); authors report an average review time of about 12 weeks; the journal's website gives an acceptance rate of 22% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Bioengineering & Translational Medicine?
According to LetPub and DOAJ records, Bioengineering & Translational Medicine is indexed in SCIE, Scopus and DOAJ.
Is Bioengineering & Translational Medicine open access, and what is the APC?
Bioengineering & Translational Medicine is a fully open-access journal. APC about USD 3,180.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .